Molecular Genetics of von Willebrand Disease


In 1926, Dr Erik von Willebrand first described the autosomal bleeding disorder that we now call von Willebrand disease (VWD). Since then, the protein responsible – eponomously named von Willebrand factor (VWF) – has been identified, the gene encoding the protein has been localized , the gene sequence has been determined and many mutations within the gene that lead to a deficiency or dysfunction of VWF and cause VWD have been characterized. Through the concerted efforts of scientists and clinicians, there is now considerable understanding of the molecular genetics of VWD and, through studies done both in vitro and in vivo, the mechanism of disease has been revealed for many of the characterized gene defects. Despite the complexities of both the VWF protein and its gene, we have a detailed picture of the molecular genetics of VWD. This review aims to provide an informative summary of current knowledge.

Key concepts

  • von Willebrand factor (VWF) is a polymeric (multimeric) blood protein that is essential for the initial stages of blood clot formation.

  • VWF has several biological activities that are important for its role in haemostasis, including binding to platelet glycoprotein Ib, coagulation factor VIII, collagen.

  • VWF has a complex biochemistry that is influenced by independent modifiers such as ABO blood group and the metalloprotease ADAMTS13.

  • von Willebrand disease (VWD) is classified into three types according to the quantity and functional activity of VWF: type 1, type 2 and type 3. Type 2 VWD is further subdivided according the functional defect present: type 2A, 2B, 2M and 2N.

  • The genetic basis for VWD is highly heterogeneous; the disease shows dominant inheritance for some mutations and recessive inheritance for others.

  • Mutations that cause milder forms of the disease show variable penetrance and this, in part relates to other modifying factors such as ABO blood group and possibly ADAMTS13.

  • The relationship between cause and effect is understood for some mutations but not for all.

Keywords: von Willebrand factor; von Willebrand disease; primary haemostasis; ADAMTS13; platelets; Bleeding

Figure 1.

Structural and functional domains of VWF. (a) Internal homologies within VWF give rise to the repeated structural domains A–D (Mancuso et al., ; Verweij et al., ). The C‐terminus contains a cysteine‐rich region known as the cysteine knot (CK) domain. Numbers within each domain correspond to exons in VWF; the scale below the domains represents amino acid residue number (the translation initiation methionine is residue 1). (b) Schematic showing the extent of pre‐, pro‐ and mature VWF (Verweij et al., ). (c) VWF functional domains and ADAMTS13 proteolysis site relative to pre‐pro‐VWF (panel B) and the structural domains of the protein (panel A). RGD abbreviates the peptide motif Arg‐Gly Asp recognized by GPIIbIIIa. (d) Distribution of mutations found in VWD type 1, 2A, 2B, 2M and 2N (based on the international VWF database at URL on 5 June 2008). In type 2M VWD, the single mutation in domain A3 (p.Ser1731Thr) is listed as ‘unclassified’ in the international database; however its attributes are consistent with the current definition of type 2M VWD.

Figure 2.

Multimer profiles for plasma VWF. Normal plasma (N) contains multimers ranging from (LMW) to (HMW). Each main multimer band is accompanied by an upper satellite band and a lower satellite band, giving the appearance of a triplet structure. The satellite bands are produced by ADAMTS13 proteolysis. Two different profiles found in type 1 VWD are illustrated, one showing a quantitative decrease in VWF but otherwise normal profile, the other showing ultra‐large VWF in the presence of multimers that show decreased proteolysis (Vicenza). The type 2A VWD plasma illustrated reflects a Group 2 mutation causing increased ADAMTS13‐mediated proteolysis, evidenced by a relative increase in the satellite bands concurrent with the loss of high‐ and intermediate‐molecular weight multimers. The type 2B VWD plasma illustrated lacks HMW multimers, and the triplet structure suggests enhanced proteolysis by ADAMTS13. The multimer analysis shown is from the author's laboratory.

Figure 3.

A Model for VWF participation in clot formation. (a) At a site of vessel damage, activated endothelial cells (grey) release VWF which remains anchored to the luminal cell surface. (b) The flow of passing blood stretches VWF and subjects it to shear stress. (c) The GPIb binding sites on VWF are exposed and platelets bind. (d) The VWF‐platelet string may interact with collagen in the subendothelium; alternatively the VWF, which is under shear stress in the blood flow, may be proteolysed by ADAMTS13. Clot growth reflects, in part, the balance between these occurrences. This model could also be applied to plasma VWF bound to collagen at exposed subendothelium, and to VWF released from aggregating activated platelets.

Figure 4.

Schematic of plasma VWF multimer profiles in various subtypes of VWD. Profiles reflect the steady balance of all biochemical processes from translation to clearance. Defects may affect more than one process directly or indirectly. For example, in type 2A VWD, some defects in the A2 domain greatly enhance proteolysis, whereas defects in the D2 or CK domains compromise multimerization and proteolysis is minimal or abnormal. Some defects affect only VWF function and do not alter the multimer profile (e.g. type 2N). A normal multimer profile is illustrated on the left hand side (N). Profiles are depicted above VWF to illustrate that the location of a defect often reflects its effect upon the protein. It is important to note that the profiles shown are not restricted to mutations in the areas indicated. For example, the type 2A (IIC) profile can also arise from mutations in the D3 domain, whereas mutation of the CK domain can cause a type 2A (IIE) pattern. IIA, IIB, IIC, IID and IIE refer to historic nomenclature for the identification of subtypes. Type 2M mutations (see text) are not represented in this schematic.



Bird AP (1980) DNA methylation and the frequency of CpG in animal DNA. Nucleic Acids Research 8: 1499–1504.

Bodó I, Katsumi A, Tuley EA et al. (2001) Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins. Blood 98: 2973–2979.

Bowen DJ and Collins PW (2004) An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13. Blood 103: 941–947.

Bowen DJ and Collins PW (2006) Insights into von Willebrand factor proteolysis: clinical implications. British Journal of Haematology 133: 457–467.

Bowen DJ, Collins PW, Lester W et al. (2005) The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co‐segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype. British Journal of Haematology 130: 462–463.

Budde U and Schneppenheim R (2008) Laboratory diagnostic work‐up and influence of DDAVP on VWF mutlimeric pattern: implication for the classification of VWD. In: Michiels JJ (ed.) Proceedings of the European VWF VWD Workshop, Antwerp. Antwerp: University Press Antwerp.

Casaña P, Martínez F, Haya S, Espinós C and Aznar JA (2001) Significant linkage and non‐linkage of type 1 von Willebrand disease to the von Willebrand factor gene. British Journal of Haematology 115: 692–700.

Casonato A, Pontara E, Sartorelo F et al. (2001) Type 2M von Willebrand disease variant characterized by abnormal multimerisation. Journal of Laboratory and Clinical Medicine 137: 70–76.

Casonato A, Sartorello F, Cattini MG et al. (2003) An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant. Blood 101: 151–156.

Castaman G, Eikenboom JC, Bertina RM and Rodeghiero F (1999) Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thrombosis and Haemostasis 82: 1065–1070.

Celikel R, Ruggeri ZM and Varughese KI (2000) von Willebrand factor conformation and adhesive function is modulated by an internalized water molecule. Nature Structural Biology 7: 881–884.

Cumming A, Grundy P and Keeney S (2006) An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thrombosis and Haemostasis 96: 630–641.

Davies JA, Collins PW, Hathaway LS and Bowen DJ (2007) Effect of von Willebrand factor Y/C1584 on in vivo protein level and function and interaction with ABO blood group. Blood 109: 2840–2846.

Davies JA, Collins PW, Hathaway LS and Bowen DJ (2008) von Willebrand factor: evidence for variable clearance in vivo according to Y/C1584 phenotype and ABO blood group. Journal of Thrombosis and Haemostasis 6: 97–103.

Dent JA, Berkowitz SD, Ware J, Kasper CK and Ruggeri ZM (1990) Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proceedings of the National Academy of Sciences of the USA 87: 6306–6310.

Dent JA, Galbusera M and Ruggeri ZM (1991) Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. Journal of Clinical Investigation 88: 774–782.

Dong JF (2005) Cleavage of ultra‐large von Willebrand factor by ADAMTS‐13 under flow conditions. Journal of Thrombosis and Haemostasis 3: 1710–1716.

Eikenboom JC, Vink T, Briët E, Sixma JJ and Reitsma PH (1994) Multiple substitutions in the von Willebrand factor gene that mimic the pseudogene sequence. Proceedings of the National Academy of Science of the USA 91: 2221–2224.

Fischer BE, Thomas KB, Schlokat U and Dorner F (1998) Triplet structure of human von Willebrand factor. Biochemistry Journal 331: 483–488.

Foster PA, Fulcher CA, Marti T, Titani K and Zimmerman TS (1987) A major factor VIII binding domain resides within the amino‐terminal 272 amino acid residues of von Willebrand factor. Journal of Biological Chemistry 262: 8443–8446.

Furlan M, Robles R and Lämmle B (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87: 4223–4234.

Goodeve A, Eikenboom J, Castaman G et al. (2007) Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM‐1VWD). Blood 109: 112–121. Erratum in: Blood 111: 3299–3300, 2008.

Holmberg L, Dent JA, Schneppenheim R et al. (1993) von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure. Journal of Clinical Investigation 91: 2169–2177.

Huizinga EG, Tsuji S, Romijn RA et al. (2002) Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science 297: 1176–1179.

James PD, Notley C, Hegadorn C et al. (2007) The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 109: 145–154.

Kaufman RJ, Dorner AJ and Fass DN (1999) von Willebrand factor elevates plasma factor VIII without induction of factor VIII messenger RNA in the liver. Blood 93: 193–197.

Lanke E, Johansson AM, Halldén C and Lethagen S (2005) Genetic analysis of 31 Swedish type 1 von Willebrand disease families reveals incomplete linkage to the von Willebrand factor gene and a high frequency of a certain disease haplotype. Journal of Thrombosis and Haemostasis 3: 2656–2663.

Lethagen S, Isaksson C, Schaedel C and Holmber L (2002) von Willebrand's disease caused by compound heterozygosity for a substitution mutation (T1156M) in the D3 domain of the von Willebrand factor and a stop mutation (Q2470X). Thrombosis and Haemostasis 88: 4243–4244.

Lyons SE, Bruck ME, Bowie EJ and Ginsburg D (1992) Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. Journal of Biological Chemistry 267: 4424–4430.

Mancuso DJ, Tuley EA, Westfield LA et al. (1989) Structure of the gene for human von Willebrand factor. Journal of Biological Chemistry 264: 19514–19527.

Mancuso DJ, Tuley EA, Westfield LA et al. (1991) Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry 30: 253–269.

Mannucci PM, Lombardi R, Castaman G et al. (1988) von Willebrand disease “Vicenza” with larger‐than‐normal (supranormal) von Willebrand factor multimers. Blood 71: 65–70.

Morales LD, Martin C and Cruz MA (2006) The interaction of von Willebrand factor‐A1 domain with collagen: mutation G1324S (type 2M von Willebrand disease) impairs the conformational change in A1 domain induced by collagen. Journal of Thrombosis and Haemostasis 4: 417–425.

Nilsson IM (1999) Commentary to Erik von Willebrand's original paper from 1926 ‘Hereditär Pseudohemifili’. Haemophilia 5: 220–221.

O'Brien LA, James PD, Othman M et al. (2003) Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood 102: 549–557.

O'Brien LA, Sutherland JJ, Hegadorn C et al. (2004) A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers. Journal of Thrombosis and Haemostasis 2: 1135–1142.

Rayes J, Hommais A, Legendre P et al. (2007) Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS‐13. Journal of Thrombosis and Haemostasis 5: 321–328.

Ribba AS, Loisel I, Lavergne JM et al. (2001) Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thrombosis and Haemostasis 86: 848–854.

Sadler JE, Budde U, Eikenboom JC et al. (2007) Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand factor. Journal of Thrombosis and Haemostasis 5: 647–649.

Sporn LA, Marder VJ and Wagner DD (1989) Differing polarity of the constitutive and regulated secretory pathways for von Willebrand factor in endothelial cells. Journal of Cell Biology 108: 1283–1289.

Surdhar GK, Enayat MS, Lawson S, Williams MD and Hill FG (2001) Homozygous gene conversion in von Willebrand factor gene as a cause of type 3 von Willebrand disease and predisposition to inhibitor development. Blood 98: 248–250.

Tjernberg P, Vos HL, Castaman G, Bertina RM and Eikenboom JC (2004) Dimerisation and multimerisation defects of von Willebrand factor due to mutated cysteinine residues. Journal of Thrombosis and Haemostasis 2: 257–265.

Tsai HM (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87: 4235–4244.

Tsai HM, Sussman II, Ginsburg D et al. (1997) Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP‐1. Blood 89: 1954–1962.

Verweij CL, de Vries CJ, Distel B et al. (1985) Construction of cDNA coding for human von Willebrand factor using antibody probes for colony‐screening and mapping of the chromosomal gene. Nucleic Acids Research 13: 4699–4717.

Verweij CL, Diergaarde PJ, Hart M and Pannekoek H (1986) Full‐length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO Journal 5: 1839–1847. Erratum in: EMBO Journal 5: 3074, 1986.

Verweij CL, Hart M and Pannekoek H (1987) Expression of variant von Willebrand factor (vWF) cDNA in heterologous cells: requirement of the pro‐polypeptide in vWF multimer formation. EMBO Journal 6: 2885–2890.

von Willebrand EA (1926) Hereditär Pseudohemifili. Finska Läekaresällskapets Handlingar 67: 87–112.

Wagner DD and Marder VJ (1984) Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localisation. Journal of Cell Biology 99: 2123–2130.

Wise RJ, Pittman DD, Handin RI, Kaufman RJ and Orkin SH (1988) The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers. Cell 52: 229–236.

Further Reading

Collins PW, Cumming AM, Goodeve AC and Lillicrap D (2008) Type 1 von Willebrand disease: application of emerging data to clinical practice. Haemophilia, May 28. [Epub ahead of print] PMID: 18510569.

Eikenboom JC (2001) Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Practice & Research. Clinical Haematology 14: 365–379.

Mazurier C, Goudemand J, Hilbert L et al. (2001) Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Practice & Research. Clinical Haematology 14: 337–347.

Mendolicchio GL and Ruggeri ZM (2005) New perspectives on von Willebrand factor functions in hemostasis and thrombosis. Seminars in Hematology 42: 5–14.

Meyer D, Fressinaud E, Hilbert L et al. (2001) Type 2 von Willebrand disease causing defective von Willebrand factor‐dependent platelet function. Best Practice & Research. Clinical Haematology 14: 349–364.

Michiels JJ (ed.) (2008) Proceedings of the European VWF VWD Workshop. Antwerp: University Press Antwerp.

Tuddenham EGD and Cooper DN (1994) The molecular genetics of haemostasis and its inherited disorders. In: Tuddenham EGD and Cooper DN (eds) Osford Monographs on Medical Genetics No 25. Oxford: Oxford Medical Publications.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
John Bowen, Derrick(Dec 2008) Molecular Genetics of von Willebrand Disease. In: eLS. John Wiley & Sons Ltd, Chichester. [doi: 10.1002/9780470015902.a0021447]